Trial Profile

A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor–Naïve With Selected Solid Tumors

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 15 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INCB 086550 (Primary)
Indications Bladder cancer; Carcinoma; Liver cancer; Malignant melanoma; Non-small cell lung cancer; Pelvic cancer; Renal cancer; Renal cell carcinoma; Solid tumours; Ureteral neoplasms; Urethral cancer; Urogenital cancer
Focus Therapeutic Use
Sponsors Incyte Corporation

Most Recent Events

23 May 2024 This trial has been completed in Bulgarian, according to European Clinical Trials Database record.
18 Apr 2024 Status changed from active, no longer recruiting to discontinued.
28 Jun 2023 Planned End Date changed from 23 May 2023 to 20 Aug 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com